• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ-C30):伊朗版本的翻译与验证研究

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version.

作者信息

Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M, Haji-Mahmoodi M

机构信息

Iranian Centre for Breast Cancer (ICBC), PO Box 13185-1488, Tehran, Iran.

出版信息

Support Care Cancer. 1999 Nov;7(6):400-6. doi: 10.1007/s005200050300.

DOI:10.1007/s005200050300
PMID:10541982
Abstract

The objective of this study was to test the reliability and validity of the Iranian version of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). The English-language version of the questionnaire was translated into Persian (Iranian language), and its final form was approved by the EORTC Study Group on Quality of Life before it was used in this study. The questionnaire was administered at two time points to a consecutive sample of 168 newly diagnosed breast cancer patients, and almost all of them (99%) found the questions easy to understand and acceptable. Crohnbach's alpha coefficient for multi-item scales (to test reliability) ranged from 0.48 to 0.95 at baseline and from 0.52 to 0.98 at follow-up administration of the questionnaire. Validity was checked using two methods: inter-scale correlation and known-groups comparison. Almost all inter-scale correlations were statistically significant in the expected direction. Known-groups comparison analysis showed that all functioning and symptom scales discriminated between subgroups of patients differing in clinical status as defined by their performance status and disease stage. In general, the findings of this study indicate that the Iranian version of the EORTC QLQ-C30 is a reliable and valid measure of quality of life in cancer patients and can be used in clinical trials and studies of outcome research in oncology.

摘要

本研究的目的是检验欧洲癌症研究与治疗组织(EORTC)生活质量问卷(QLQ-C30)伊朗版本的信度和效度。该问卷的英文版本被翻译成波斯语(伊朗语言),其最终版本在本研究使用之前得到了EORTC生活质量研究小组的批准。该问卷在两个时间点对168例新诊断的乳腺癌患者连续样本进行了施测,几乎所有患者(99%)都认为问题易于理解且可以接受。多项目量表的克朗巴赫α系数(用于检验信度)在基线时范围为0.48至0.95,在问卷随访施测时范围为0.52至0.98。效度使用两种方法进行检验:量表间相关性和已知组比较。几乎所有量表间相关性在预期方向上都具有统计学意义。已知组比较分析表明,所有功能和症状量表都能区分根据其体能状态和疾病分期定义的临床状态不同的患者亚组。总体而言,本研究结果表明,EORTC QLQ-C30的伊朗版本是癌症患者生活质量的可靠且有效的测量工具,可用于肿瘤学的临床试验和结局研究。

相似文献

1
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version.欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ-C30):伊朗版本的翻译与验证研究
Support Care Cancer. 1999 Nov;7(6):400-6. doi: 10.1007/s005200050300.
2
The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version.欧洲癌症研究与治疗组织乳腺癌特异性生活质量问卷(EORTC QLQ-BR23):伊朗版本的翻译与验证研究
Qual Life Res. 2000 Mar;9(2):177-84. doi: 10.1023/a:1008918310251.
3
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.欧洲癌症研究与治疗组织QLQ-C30:一种用于肿瘤学国际临床试验的生活质量评估工具。
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
4
The Azeri Version of European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30): Translation and Validation.欧洲癌症研究与治疗组织核心生活质量问卷(EORTC QLQ-C30)阿塞拜疆语版本:翻译与验证
Asian Pac J Cancer Prev. 2020 Jan 1;21(1):267-271. doi: 10.31557/APJCP.2020.21.1.267.
5
Validity and reliability of the Swedish version of the Memorial Symptom Assessment Scale (MSAS): an instrument for the evaluation of symptom prevalence, characteristics, and distress.《纪念症状评估量表(MSAS)瑞典语版的有效性和可靠性:用于评估症状发生率、特征和痛苦的工具》。
J Pain Symptom Manage. 2013 Jul;46(1):131-41. doi: 10.1016/j.jpainsymman.2012.07.023. Epub 2012 Nov 27.
6
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): validation study of the Thai version.欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ-C30):泰语版的效度研究
Qual Life Res. 2006 Feb;15(1):167-72. doi: 10.1007/s11136-005-0449-7.
7
Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.使用欧洲癌症研究与治疗组织核心生活质量问卷(QLQ-C30)对韩国样本中接受癌症疼痛管理的晚期患者的生活质量变化进行评估。
Oncology. 2008;74 Suppl 1:7-12. doi: 10.1159/000143212. Epub 2008 Aug 28.
8
The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.欧洲癌症研究与治疗组织QLQ-C30:对欧洲癌症研究与治疗组织QLQ-C30土耳其语版本的文化效度和信度的考察。
Eur J Cancer Care (Engl). 2004 May;13(2):135-44. doi: 10.1111/j.1365-2354.2003.00435.x.
9
Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.欧洲癌症研究与治疗组织核心问卷(EORTC QLQ-C30)电子患者报告结局(e-PRO)工具用于测量乳腺癌患者健康相关生活质量的可靠性:前瞻性随机试验
J Med Internet Res. 2017 Sep 14;19(9):e322. doi: 10.2196/jmir.8210.
10
Validation study of a quality of life (QOL) questionnaire for use in Iran.用于伊朗的生活质量(QOL)问卷的验证研究。
Asian Pac J Cancer Prev. 2007 Oct-Dec;8(4):543-6.

引用本文的文献

1
Economic burden and quality of life caused by non-hodgkin lymphoma cancer in Iran.伊朗非霍奇金淋巴瘤所致的经济负担及生活质量
J Health Popul Nutr. 2025 Aug 6;44(1):280. doi: 10.1186/s41043-025-01033-8.
2
Quality of life, insomnia, attitudes and beliefs in women undergoing chemotherapy for breast cancer: a cross-sectional study in Amol city Northern Iran.乳腺癌化疗女性的生活质量、失眠、态度和信念:伊朗北部阿莫勒市的一项横断面研究
BMC Womens Health. 2025 Jul 3;25(1):303. doi: 10.1186/s12905-025-03853-6.
3
Effect of Melatonin on Oxaliplatin Induced Neuropathy in Patients Receiving Folfox Chemotherapy Regimens for Stage II-IV Colorectal Cancer: A Randomized, Placebo Controlled, Double Blind Trial.
褪黑素对接受Folfox化疗方案治疗II-IV期结直肠癌患者奥沙利铂所致神经病变的影响:一项随机、安慰剂对照、双盲试验
Health Sci Rep. 2025 May 19;8(5):e70619. doi: 10.1002/hsr2.70619. eCollection 2025 May.
4
The Persian Version of the Fear of Progression Questionnaire's Short Form (FOPQ-SF): Psychometric Features Among Cancer Patients.《恐惧进展问卷短式量表(FOPQ-SF)的波斯语版:癌症患者的心理计量特征》。
J Gastrointest Cancer. 2024 Oct 26;56(1):11. doi: 10.1007/s12029-024-01115-6.
5
Analyzing quality of life after low anterior resection for rectal cancer.分析直肠癌低位前切除术后的生活质量。
Ir J Med Sci. 2024 Dec;193(6):2643-2652. doi: 10.1007/s11845-024-03757-8. Epub 2024 Aug 5.
6
Effect of on Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Randomized Trial.[具体药物或干预措施]对癌症患者化疗引起的周围神经病变的影响:一项随机试验。 (这里原文中“Effect of ”部分缺失具体内容,翻译时按照格式要求保留了空缺,实际应用中应补充完整)
Int J Hematol Oncol Stem Cell Res. 2024 Apr 1;18(2):165-173. doi: 10.18502/ijhoscr.v18i2.15372.
7
The supportive care needs survey short form 34 (SCNS-SF34): translation and cultural adaptation into the Nepali language among patients with cervical cancer in Nepal.支持性照顾需求调查简表 34 项(SCNS-SF34):在尼泊尔宫颈癌患者中翻译成尼泊尔语并进行文化调适。
Health Qual Life Outcomes. 2023 Aug 23;21(1):98. doi: 10.1186/s12955-023-02147-5.
8
Construction of a system for head and neck tumor traceless resection with non-inflatable transaxillary total endoscopic surgery.构建非充气经腋窝全内镜手术下无痕迹头颈部肿瘤切除术系统。
World J Surg Oncol. 2023 Jul 26;21(1):221. doi: 10.1186/s12957-023-03033-6.
9
Integrated radiomics, dose-volume histogram criteria and clinical features for early prediction of saliva amount reduction after radiotherapy in nasopharyngeal cancer patients.综合放射组学、剂量体积直方图标准和临床特征用于早期预测鼻咽癌患者放疗后唾液量减少
Discov Oncol. 2022 Dec 30;13(1):145. doi: 10.1007/s12672-022-00606-x.
10
Self-care behaviors mediates the relationship between resilience and quality of life in breast cancer patients.自我护理行为在乳腺癌患者的韧性和生活质量之间起中介作用。
BMC Psychiatry. 2022 Dec 26;22(1):825. doi: 10.1186/s12888-022-04470-5.